实用医学杂志 ›› 2021, Vol. 37 ›› Issue (12): 1603-1606.doi: 10.3969/j.issn.1006⁃5725.2021.12.018

• 临床研究 • 上一篇    下一篇

舌下含服粉尘螨滴剂治疗螨过敏类变应性鼻炎患儿不同疗程的疗效

刘飞1,李烁1,梁俊毅1, 黄丹琳1, 罗彬2, 邢枭1, 汪志伟2   

  1.  1 华中科技大学协和深圳医院耳鼻喉科(广东深圳 518000);2 珠海市人民医院(暨南大学附属珠海医院)耳鼻咽喉头颈外科(广东珠海 519000)

  • 出版日期:2021-06-25 发布日期:2021-06-25
  • 通讯作者: 汪志伟 E⁃mail:31952929 @qq.com

The efficacy of sublingual immunotherapy with dermatophagoides farinae drops for mite allergen⁃induced allergic rhinitis at different treatment courses in children 

LIU Fei,LI Shuo,LIANG Junyi,HUANG Dan⁃ ling,LUO Bin,XING Xiao,WANG Zhiwei.    

  1. Department of Otolaryngology,Huazhong University of Science and Technology Union Shenzhen Hospital,Shenzhen 518000,China 

  • Online:2021-06-25 Published:2021-06-25
  • Contact: WANG Zhiwei E⁃mail:31952929 @qq.com

摘要:

目的 分析螨过敏类变应性鼻炎(AR)患儿行粉尘螨滴剂舌下含服不同疗程的疗效情况。 方法 回顾性分析 2013 年以来就诊于华中科技大学协和深圳医院(南山医院)耳鼻喉科的螨过敏 AR 患儿 120例,随访资料齐全且已完成4年疗程舌下含服免疫方法(SILT),治疗前、治疗期间间隔3个月开展随访 就结束治疗后分别评估鼻炎症状评分(TNSS)、鼻炎用药评分(TRMS)、视觉模拟量表(VAS)及鼻结膜炎生活质量量表(RQLQ)评分以及不良反应情况。结果 与治疗前相比,SLIT治疗1年结束时TNSS、TRMS、VAS评分、 RQLQ 评分均有显著改善(P<0.05);与 SLIT 1 年疗程相比,SLIT 治疗 2 年结束时 TNSS、TRMS、VAS、RQLQ 评分均有显著改善(P<0.05)。与SLIT 2年疗程相比,SLIT治疗3年结束时VAS、RQLQ评分均有显著性改善 P<0.05)。与SLIT 3年疗程相比,SLIT治疗4年结束时TNSS、TRMS、VAS、RQLQ评分差异均无统计学意义 P>0.05)。治疗1、2、3年及4年结束时,患儿的不良反应发生率对比差异无统计学意义(P>0.05),所有患儿 均未出现严重不良反应。结论 螨过敏AR患儿开展超过2年粉尘螨滴剂舌下含服疗效较1年更佳,3年疗 VAS及RQLQ评分改善较2年更明显,因此患儿至少需坚持2年治疗,3年是最佳疗程。

关键词:

螨过敏, 粉尘螨滴剂, 舌下含服, 变应性鼻炎, 疗程

Abstract:

Objective To explore the efficacy of sublingual immunotherapy(SLIT)with dermatophagoi⁃ des farinae drops in the treatment of mite allergen⁃induced allergic rhinitis(AR)at different treatment courses in children. Methods The data on 120 pediatric patients with mite allergen⁃induced AR,who had been treatment in the ENT department of Huazhong University of Science and Technology Union Shenzhen Hospital since 2013,were reviewed. Integral follow⁃up data was collected and a four⁃year course of treatment with SLIT was completed. A follow⁃up was started before therapy and every three months during the treatment. After therapy,total nasal symptom score(TNSS),total rhinitis medication scores(TRMS),visual analogue scale(VAS),and rhinoconjunctivitis quality of life questionnaire(RQLQ)scores were assessed;and adverse reactions were recorded. Results After one⁃year SLIT,TNSS,TRMS,VAS and RQLQ scores were significantly improved than the baselines(P < 0.05); TNSS,TRMS,VAS and RQLQ scores,as compared with the one ⁃year therapy,were significantly improved two years after SLIT(P < 0.05). VAS and RQLQ scores on the three⁃year therapy with SLIT were significantly improved than those on the two⁃year treatment with SLIT(P < 0.05). TNSS,TRMS,VAS and RQLQ scores did not differ significantly between the three⁃year and the four⁃year therapies(P > 0.05). There were no significant differences in the rate of adverse events among the one⁃year,two⁃year,three⁃year and four⁃year therapies(P > 0.05). All the pediatric patients had no serious adverse reactions. Conclusions More than two years of SLIT,as compared with one year of therapy,has better effects for mite allergen⁃induced AR in children. VAS and RQLQ scores on the three⁃ year therapy with SLIT improve more markedly than those on the two⁃year therapy. Therefore,children should be treated for at least two years,and the 3⁃year therapy is the optimal course.

Key words:

mite allergen, dermatophagoides farinae drops, sublingual, allergic rhinitis, treatment course